Non-nucleoside structured compounds with antiviral activity—past 10 years (2010–2020)Review Published on 2022-01-192023-07-01 Journal: European journal of medicinal chemistry [Category] SARS, [키워드] Antiviral agents antiviral therapy clinical trials COVID-19 Non-nucleosides [DOI] 10.1016/j.ejmech.2022.114136 PMC 바로가기 [Article Type] Review
JIB-04 Has Broad-Spectrum Antiviral Activity and Inhibits SARS-CoV-2 Replication and Coronavirus PathogenesisResearch Article Published on 2022-01-182022-10-29 Journal: mBio [Category] COVID-19, COVID19(2023년), MERS, SARS, [키워드] 50% effective concentration activity acute respiratory syndrome administration Antiviral antiviral activity Antiviral agents approach bronchial epithelial cells cell types compound screening coronavirus Coronavirus infection DNA and RNA gastroenteritis global public health greater highlight in vitro in vivo inhibited inhibitor JIB-04 reduced Replication reporter SARS-CoV-2 SARS-CoV-2 replication specificity survival tissue pathology utility Vero E6 cell viral pathogens virus virus infection viruses [DOI] 10.1128/mbio.03377-21 PMC 바로가기 [Article Type] Research Article
The Conserved Macrodomain Is a Potential Therapeutic Target for Coronaviruses and AlphavirusesPerspective Published on 2022-01-142022-10-28 Journal: Pathogens [Category] COVID-19, [키워드] acting addition ADP-ribosylation ADP-ribosylhydrolase alphavirus Antiviral Antiviral agents antiviral target antivirals approaches binding pocket combating Combination combination therapy complement conserved Coronaviral coronavirus Coronaviruses COVID-19 COVID-19 pandemic Critical demonstrated develop drug target effective Host inhibitor interferon interferon response lack macrodomain Mutation offer pandemic Pathogenesis Potential protease Protective public health Replication responses RNA polymerase SARS-CoV-2 suppresse target targets Therapeutics Threats Treatment Vaccines viral disease Viral macrodomain virus virus replication [DOI] 10.3390/pathogens11010094 PMC 바로가기 [Article Type] Perspective
The Broad-Spectrum Antiviral Potential of the Amphibian Peptide AR-23Article Published on 2022-01-142022-10-29 Journal: International Journal of Molecular Sciences [Category] COVID-19, SARS, [키워드] activity Amphibian antimicrobial peptide antimicrobial peptides antiviral activity antiviral agent Antiviral agents antiviral drug antiviral drugs antiviral molecule antiviral therapy contrary coronavirus DNA DNA and RNA drugs early stage effective evaluated exhibited greater HCoV-229E HSV-1 identify inactive indicated Infection inhibitory activity investigated peptide peptides performed Potential reported RNA SARS-CoV-2 secretion strain therapeutic effect therapeutic options variety viral infections virus viruses [DOI] 10.3390/ijms23020883 PMC 바로가기 [Article Type] Article
Molecular Modeling and Preliminary Clinical Data Suggesting Antiviral Activity for Chlorpheniramine (Chlorphenamine) Against COVID-19Infectious Disease Published on 2022-01-062022-10-31 Journal: Cureus [Category] COVID-19, [키워드] activity acute respiratory syndrome Against antiviral activity Antiviral agents cause Chlorphenamine Chlorpheniramine chlorpheniramine maleate clinical clinical evidence Clinical findings coronavirus disease Coronavirus-2 COVID-19 include indicate modeling Molecular modeling SARS-CoV-2 similarity Structure Support the Betacoronavirus [DOI] 10.7759/cureus.20980 PMC 바로가기 [Article Type] Infectious Disease
Synthesis and In Vitro Study of Antiviral Activity of Glycyrrhizin Nicotinate Derivatives against HIV-1 Pseudoviruses and SARS-CoV-2 VirusesHIV-1 슈도바이러스 및 SARS-CoV-2 바이러스에 대한 글리시리진 니코틴산 유도체의 항바이러스 활성 합성 및 시험관 내 연구Article Published on 2022-01-042022-09-10 Journal: Molecules [Category] 치료제, [키워드] activity acylation addition agent antiviral action antiviral activity Antiviral agents broad spectrum Cell Cell culture characteristics of patient characterized clinical complications co-morbidities comparable Compound COVID-19 derivative derivatives drug entry inhibitors exhibited General population Glycyrrhizinic acid higher risk HIV HIV-1 HPLC human immunodeficiency virus type 1 in vitro inhibit SARS-CoV-2 inhibitory activity investigated morbidities MTT nicotinates of glycyrrhizic acid nicotinic acid patients pseudovirus pseudovirus infection pseudoviruses Remdesivir Replication resulting SARS-CoV-2 SARS-CoV-2 replication shown strain subtype suggested synthesis target cell Toxicity Vero E6 Vero E6 cell VERO E6 cells virus entry was tested [DOI] 10.3390/molecules27010295 PMC 바로가기 [Article Type] Article
Fruit Bromelain-Derived Peptide Potentially Restrains the Attachment of SARS-CoV-2 Variants to hACE2: A Pharmacoinformatics ApproachArticle Published on 2022-01-012022-10-30 Journal: Molecules [Category] COVID-19, SARS, [키워드] Analysis Antiviral agents attachment bind binding energy binding site Bromelain Cell COVID-19 Critical determine deviation docking domain fluctuation fruit hACE2 human Angiotensin-converting enzyme human cell in silico inhibit interact Interaction MD simulation Molecular dynamics simulation Mutation peptide peptide-protein interaction radius of gyration RBD RBD binding RBD mutation RBD variant recent receptor Receptor-binding domain residue responsible RMSD RMSF SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants spike glycoprotein Spread the RBD the SARS-CoV-2 trajectory [DOI] 10.3390/molecules27010260 PMC 바로가기 [Article Type] Article
Model-based cost-effectiveness analysis of oral antivirals against SARS-CoV-2 in Korea국내 SARS-CoV-2에 대한 경구용 항바이러스제의 모델 기반 비용 효율성 분석Article Published on 2022-01-012022-09-11 Journal: Epidemiology and Health [Category] SARS, 치료제, [키워드] Admission Adult patients Adults Analysis Antiviral antiviral agent Antiviral agents calculated Care coronavirus disease Coronavirus disease 2019 Cost-effectiveness analysis country COVID-19 COVID-19 patient Efficacy Elderly patient elderly patients Emergency use group health system Hospital admission Hospitalization ICU less medical system Mild-to-moderate molnupiravir Nirmatrelvir Patient patients predicted reduce reducing Ritonavir SARS-CoV-2 Severe case severe COVID-19 Severe patient standard care symptomatic Treatment underlying disease underlying diseases [DOI] 10.4178/epih.e2022034 PMC 바로가기 [Article Type] Article
Antiviral Strategies Using Natural Source-Derived Sulfated Polysaccharides in the Light of the COVID-19 Pandemic and Major Human Pathogenic VirusesCOVID-19 Pandemic 및 주요 인간 병원성 바이러스에 비추어 천연 소스 유래 황산화 다당류를 사용한 항 바이러스 전략Review Published on 2021-12-242022-09-10 Journal: Viruses [Category] SARS, 치료제, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 antiviral activities and mechanisms antiviral activity Antiviral agents antiviral drugs antiviral efficacy antiviral potency Characteristics clinical settings contributing to coronavirus COVID-19 cytotoxicity drug drug structure-activity relationship emerging viral infections focus fraction heparin mimetics host cell Human in viral in vivo studies Infection investigated involved LIGHT Major major human pathogenic viruses majority many case many cases methodology molecular molecular mechanism molecular mechanisms molecules natural outbreak pathogenic virus Pathways polysaccharide profile Research respiratory SARS-CoV-2 severe acute respiratory syndrome Coronavirus Strategy sulfated sulfated polysaccharide sulfated polysaccharides susceptible susceptible host treat variety Viral viral infection viral infections virus entry as a target viruses [DOI] 10.3390/v14010035 PMC 바로가기 [Article Type] Review
Nebulized enriched heparin to treat no critical patients with Sars-Cov-2 Triple-blind clinical trialSars-Cov-2 삼중 맹검 임상 시험에서 중증 환자를 치료하지 않는 분무 농축 헤파린6700 Published on 2021-12-232022-09-10 Journal: Medicine [Category] 변종, 신약개발, 임상, [키워드] absence acute respiratory syndrome acute respiratory syndrome coronavirus 2 advance antiviral activity Antiviral agents ARMS both groups clinical protocol Clinical tests clinical trial collapse conducted coronavirus coronavirus 2 coronavirus disease Coronavirus disease 2019 COVID-19 Critical Diagnosis disease drug Efficacy group health systems heparin In vitro assay inhalation Intervention mechanism nebulized new virus outcome pandemic status participant Patient Placebo Pneumonia protocols Radiological Diagnosis receive Replication respiratory Respiratory disease SARS-CoV-2 selected Serious Adverse Events Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus shown Spread therapeutic approaches treat Treatment triple-blind urgency Vaccine variant Viral Viral load viral respiratory [DOI] 10.1097/MD.0000000000028288 PMC 바로가기 [Article Type] 6700